12 research outputs found

    3-D printed band-pass combline filter

    Get PDF
    This article describes a fourth-order 3-D printed combline filter with a Chebyshev response, operating at central frequency 3 GHz and having a 3% fractional bandwidth. The filter is designed using the coupling matrix theory, fabricated, and experimental results are presented. Comparison between simulations and measurements shows good agreement

    W-Band Waveguide Filters Fabricated by Laser Micromachining and 3-D Printing

    Get PDF
    This paper presents two W-band waveguide bandpass filters, one fabricated using laser micromachining and the other 3-D printing. Both filters are based on coupled resonators and are designed to have a Chebyshev response. The first filter is for laser micromachining and it is designed to have a compact structure allowing the whole filter to be made from a single metal workpiece. This eliminates the need to split the filter into several layers and therefore yields an enhanced performance in terms of low insertion loss and good durability. The second filter is produced from polymer resin using a stereolithography 3-D printing technique and the whole filter is plated with copper. To facilitate the plating process, the waveguide filter consists of slots on both the broadside and narrow side walls. Such slots also reduce the weight of the filter while still retaining the filter's performance in terms of insertion loss. Both filters are fabricated and tested and have good agreement between measurements and simulations

    Structure-activity relationship (SAR) in monosaccharide-based Toll-like receptor 4 (TLR4) antagonists

    Get PDF
    The structure-activity relationship was investigated in a series of synthetic TLR4 antagonists formed by a glucosamine core linked to two phosphate esters and two linear carbon chains. Molecular modeling showed that the compounds with 10, 12 and 14 carbons chains are associated to higher stabilization of the MD-2/TLR4 antagonist conformation than in the case of the C16 variant. Binding experiments with human MD-2 showed that the C12 and C14 variants have higher affinity than C10, while the C16 variant did not interact with the protein. The molecules, with the exception of the C16 variant, inhibited the LPS-stimulated TLR4 signal in human and murine cells and the antagonist potency mirrored the MD-2 affinity calculated from in vitro binding experiments. FT-IR, NMR, and SAXS measurements suggested that the aggregation state in aqueous solution depends on fatty acid chains lengths and that this property can influence TLR4 activity in this series of compounds

    Feasibility of a prehabilitation programme dedicated to older patients with cancer before complex medical–surgical procedures: the PROADAPT pilot study protocol

    No full text
    Background Ageing is associated with an increased prevalence of comorbidities and sarcopenia as well as a decline of functional reserve of multiple organ systems, which may lead, in the context of the disease-related and/or treatment-related stress, to functional deconditioning. The multicomponent ‘Prehabilitation & Rehabilitation in Oncogeriatrics: Adaptation to Deconditioning risk and Accompaniment of Patients’ Trajectories (PROADAPT)’ intervention was developed multiprofessionally to implement prehabilitation in older patients with cancer.Methods The PROADAPT pilot study is an interventional, non-comparative, prospective, multicentre study. It will include 122 patients oriented to complex medical–surgical curative procedures (major surgery or radiation therapy with or without chemotherapy). After informed consent, patients will undergo a comprehensive geriatric assessment and will be offered a prehabilitation kit that includes an advice booklet with personalised objectives and respiratory rehabilitation devices. Patients will then be called weekly and monitored for physical and respiratory rehabilitation, preoperative renutrition, motivational counselling and iatrogenic prevention. Six outpatient visits will be planned: at inclusion, a few days before the procedure and at 1, 3, 6 and 12 months after the end of the procedure. The main outcome of the study is the feasibility of the intervention, defined as the ability to perform at least one of the components of the programme. Clinical data collected will include patient-specific and cancer-specific characteristics.Ethics and dissemination The study protocol was approved by the Ile de France 8 ethics committee on 5 June 2018. The results of the primary and secondary objectives will be published in peer-reviewed journals.Trial registration number NCT03659123. Pre-results of the trial
    corecore